{
  "39K.F": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CENTOGENE N.V. EO -,12",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "39K.MU": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CENTOGENE N.V. EO -,12",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "CNTG": {
    "city": "Rostock",
    "country": "Germany",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Diagnostics & Research",
    "long_name": "Centogene N.V.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Centogene N.V.",
    "state": null,
    "summary": "Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
    "website": "http://www.centogene.com",
    "zipcode": "18055"
  },
  "ECX.DE": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "de_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG NA O.N.",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "ECX.F": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG NA O.N.",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "EPGNF": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "EPGNY": {
    "city": "Berlin",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Epigenomics AG",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPIGENOMICS AG",
    "state": null,
    "summary": "Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
    "website": "http://www.epigenomics.com",
    "zipcode": "10829"
  },
  "NN6.DE": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "de_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "NN6.F": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "NNGRF": {
    "city": "Marburg",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "NanoRepro AG",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NANOREPRO AG",
    "state": null,
    "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
    "website": "http://www.nanorepro.com",
    "zipcode": "35037"
  },
  "SHL.DE": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH.AG NA O.N.",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL.F": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH.AG NA O.N.",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL.VI": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTHINEERS AG",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SHL1.F": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTH ADR/0,50",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SMMNY": {
    "city": "Erlangen",
    "country": "Germany",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Siemens Healthineers AG",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SIEMENS HEALTHINEERS AG",
    "state": null,
    "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
    "website": "http://www.siemens-healthineers.com",
    "zipcode": "91052"
  },
  "SYAB.F": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "SYNLAB AG",
    "market": "dr_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "SYNLAB AG  INH O.N.",
    "state": null,
    "summary": "SYNLAB AG provides clinical laboratory and medical diagnostic services for practicing doctors, clinics, patients, and the pharmaceutical industry primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 450 laboratories and 1,600 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.",
    "website": "http://www.synlab.com",
    "zipcode": "80809"
  },
  "SYAB.VI": {
    "city": "Munich",
    "country": "Germany",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "SYNLAB AG",
    "market": "at_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "SYNLAB AG",
    "state": null,
    "summary": "SYNLAB AG provides clinical laboratory and medical diagnostic services for practicing doctors, clinics, patients, and the pharmaceutical industry primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 450 laboratories and 1,600 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.",
    "website": "http://www.synlab.com",
    "zipcode": "80809"
  }
}
